Jane Street Group LLC Sells 69,867 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

Jane Street Group LLC cut its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 32.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 147,872 shares of the biopharmaceutical company’s stock after selling 69,867 shares during the period. Jane Street Group LLC owned about 0.13% of Fate Therapeutics worth $518,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of FATE. Ausdal Financial Partners Inc. bought a new stake in Fate Therapeutics during the 2nd quarter worth approximately $33,000. Dark Forest Capital Management LP bought a new stake in Fate Therapeutics during the 2nd quarter worth approximately $63,000. DRW Securities LLC bought a new stake in Fate Therapeutics during the 2nd quarter worth approximately $71,000. Castleview Partners LLC bought a new stake in Fate Therapeutics during the 3rd quarter worth approximately $73,000. Finally, Arizona State Retirement System bought a new stake in Fate Therapeutics during the 2nd quarter worth approximately $84,000. 97.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

FATE has been the topic of a number of recent research reports. Wedbush reiterated a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, November 12th. Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a research report on Tuesday, November 19th. Finally, Bank of America upgraded Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday, November 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Fate Therapeutics has a consensus rating of “Hold” and a consensus price target of $6.75.

Fate Therapeutics Trading Up 0.6 %

Shares of Fate Therapeutics stock opened at $1.80 on Monday. The company has a market capitalization of $205.01 million, a PE ratio of -1.09 and a beta of 2.02. Fate Therapeutics, Inc. has a 12 month low of $1.55 and a 12 month high of $8.83. The stock’s fifty day simple moving average is $2.25 and its 200 day simple moving average is $3.18.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.02. The firm had revenue of $3.07 million for the quarter, compared to the consensus estimate of $0.88 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. Analysts predict that Fate Therapeutics, Inc. will post -1.72 EPS for the current fiscal year.

Insider Activity

In related news, Director Redmile Group, Llc acquired 397,964 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was bought at an average price of $1.68 per share, for a total transaction of $668,579.52. Following the acquisition, the director now directly owns 12,884,277 shares of the company’s stock, valued at approximately $21,645,585.36. The trade was a 3.19 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.00% of the stock is owned by corporate insiders.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.